Cargando…

Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion

Cancer cachexia is a multilayered syndrome consisting of the interaction between tumor cells and the host, at times modulated by the pharmacologic treatments used for tumor control. Key cellular and soluble mediators, activated because of this interaction, induce metabolic and nutritional alteration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Currow, David C., Maddocks, Matthew, Cella, David, Muscaritoli, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275064/ https://www.ncbi.nlm.nih.gov/pubmed/30400622 http://dx.doi.org/10.3390/ijms19113471

Ejemplares similares

ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
por: Currow, D., et al.
Publicado: (2017)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
por: Pietra, Claudio, et al.
Publicado: (2014)

Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023)

Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC
por: Blauwhoff-Buskermolen, Susanne, et al.
Publicado: (2017)

Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
por: Anker, Stefan D, et al.
Publicado: (2015)

Ghrelin for cachexia
por: Akamizu, Takashi, et al.
Publicado: (2010)

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
por: Takayama, Koichi, et al.
Publicado: (2016)

Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
por: Garcia, Jose M, et al.
Publicado: (2014)

Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
por: Graf, Solomon A, et al.
Publicado: (2017)

Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)

Oncology Update: Anamorelin
por: Prommer, Eric
Publicado: (2017)

Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia
por: Takeda, Tsuyoshi, et al.
Publicado: (2022)

The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
por: Wakabayashi, Hidetaka, et al.
Publicado: (2020)

Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model
por: Northrup, R., et al.
Publicado: (2013)

An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin
por: Leese, Philip T, et al.
Publicado: (2015)

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022)

The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis
por: Taniguchi, Jumpei, et al.
Publicado: (2023)

Chronic Renal Failure, Cachexia, and Ghrelin
por: Laviano, A., et al.
Publicado: (2010)

Novel mechanism of ghrelin therapy for cachexia
por: Hatanaka, Michiyoshi, et al.
Publicado: (2015)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia
por: Hamauchi, Satoshi, et al.
Publicado: (2019)

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
por: Oshima, Yuri, et al.
Publicado: (2022)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index
por: Naito, Tateaki, et al.
Publicado: (2022)

Refractory Monomorphic Ventricular Tachycardia Induced by Anamorelin
por: Sakagami, Hiroaki, et al.
Publicado: (2022)

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
por: Katakami, Nobuyuki, et al.
Publicado: (2017)

Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery
por: T. de Barros, Cecilia, et al.
Publicado: (2020)

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Natural ghrelin in advanced cancer patients with cachexia, a case series
por: Blum, David, et al.
Publicado: (2021)

Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia
por: Salsman, John M., et al.
Publicado: (2014)

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia
por: Müller, Timo D., et al.
Publicado: (2010)

Rikkunshito, a ghrelin potentiator, ameliorates anorexia–cachexia syndrome
por: Fujitsuka, Naoki, et al.
Publicado: (2014)

Experts Opinion
por: Goldberg, Ivan, et al.
Publicado: (2012)

Expert Opinion
Publicado: (1920)

Potentiation of ghrelin signaling attenuates cancer anorexia–cachexia and prolongs survival
por: Fujitsuka, N, et al.
Publicado: (2011)

Appetite and food intake results from phase I studies of anamorelin
por: Blum, Robert A., et al.
Publicado: (2019)

Liquid Biopsy for Cancer Cachexia: Focus on Muscle-Derived microRNAs
por: Belli, Roberta, et al.
Publicado: (2021)

Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial)
por: Sousa, Mariana S., et al.
Publicado: (2023)

Side Chain Orientation of Tryptophan Analogues Determines Agonism and Inverse Agonism in Short Ghrelin Peptides
por: Nicke, Lennart, et al.
Publicado: (2019)

Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia
por: Salade, Laurent, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qn3n52bjeugthgdlr5p1pecmb1